Morrisville, NC – According to filings with the U.S. Securities and Exchange Commission, Locus Biosciences is raising $19,983,396.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Paul Garofolo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Locus Biosciences
Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA. Locus Biosciences has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria. Guided by the custom Locus Bio CRISPRs, the Type-I Cas proteins work to destroy bacterial DNA and cause the bacterial targets to self-destruct. Locus platform enables the development of antimicrobials which avoid currently known resistance mechanisms while leaving non-target bacteria unharmed. Built on prokaryotic technology for prokaryotic targets, Locus is advancing its platform to create therapeutics for critical-need therapeutic areas ranging from resistant bacterial infections to the microbiome.

To learn more about Locus Biosciences, visit http://www.locus-bio.com/

Contact:
Paul Garofolo, Chief Executive Officer
919-495-4510
paul.garofolo@locus-bio.com
https://www.linkedin.com/in/paulgarofolo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved